PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
In vitro and in vivo models show inhibition of tumorigenesis, metastasis, and cancer growth through apoptosis induction and cell cycle alteration [PMID:22099605, PMID:31078746].
Animal models and human subjects suggest a neuroprotective role in preventing and treating dementia syndromes, with pterostilbene appearing more effective than resveratrol in combatting associated brain changes [PMID:29168580].
Animal models demonstrate reduced weight gain, liver fat, plasma cholesterol, adiposity, and blood glucose [PMID:32125846, PMID:37486219].
In a Wistar rat model, pterostilbene showed potential for treating severe acute pancreatitis [PMID:27525946].
In aged mice, short-term and long-term ingestion increased implantation and live birth rates and improved oocyte quality [PMID:40711451].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 23808710 (2013) — Pterostilbene: Biomedical applications. · Critical reviews in clinical laboratory sciences
- 2.PMID: 29377302 (2018) — Vaccinium angustifolium (lowbush blueberry) leaf extract increases extravillous trophoblast cell migration and invasion in vitro. · Phytotherapy research : PTR
- 3.PMID: 29168580 (2018) — Resveratrol, pterostilbene, and dementia. · BioFactors (Oxford, England)
- 4.PMID: 32623832 (2020) — Into the wild blueberry (Vaccinium angustifolium) rhizosphere microbiota. · Environmental microbiology
- 5.PMID: 32125846 (2020) — Chemistry of Pterostilbene and Its Metabolic Effects. · Journal of agricultural and food chemistry